|
1
|
Ponikowski P, Voors AA, Anker SD, Bueno H,
Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP,
Jankowska EA, et al: 2016 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure: The Task Force for
the diagnosis and treatment of acute and chronic heart failure of
the European Society of Cardiology (ESC). Developed with the
special contribution of the Heart Failure Association (HFA) of the
ESC. Eur J Heart Fail. 18:891–975. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
González A, Schelbert EB, Díez J and
Butler J: Myocardial interstitial fibrosis in heart failure:
Biological and translational perspectives. J Am Coll Cardiol.
71:1696–1706. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Talman V and Ruskoaho H: Cardiac fibrosis
in myocardial infarction-from repair and remodeling to
regeneration. Cell Tissue Res. 365:563–581. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kong P, Christia P and Frangogiannis NG:
The pathogenesis of cardiac fibrosis. Cell Mol Life Sci.
71:549–574. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Porter KE and Turner NA: Cardiac
fibroblasts: At the heart of myocardial remodeling. Pharmacol Ther.
123:255–278. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
van den Borne SW, Diez J, Blankesteijn WM,
Verjans J, Hofstra L and Narula J: Myocardial remodeling after
infarction: The role of myofibroblasts. Nat Rev Cardiol. 7:30–37.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Travers JG, Kamal FA, Robbins J, Yutzey KE
and Blaxall BC: Cardiac fibrosis: The fibroblast awakens. Circ Res.
118:1021–1040. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kawaguchi M, Takahashi M, Hata T, Kashima
Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J,
et al: Inflammasome activation of cardiac fibroblasts is essential
for myocardial ischemia/reperfusion injury. Circulation.
123:594–604. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Frangogiannis NG: The inflammatory
response in myocardial injury, repair, and remodelling. Nature
Reviews Cardiology. 11:255–265. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Brown RD, Ambler SK, Mitchell MD and Long
CS: The cardiac fibroblast: Therapeutic target in myocardial
remodeling and failure. Annu Rev Pharmacol Toxicol. 45:657–687.
2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Park S, Ranjbarvaziri S, Lay FD, Zhao P,
Miller MJ, Dhaliwal JS, Huertas-Vazquez A, Wu X, Qiao R, Soffer JM,
et al: Genetic regulation of fibroblast activation and
proliferation in cardiac fibrosis. Circulation. 138:1224–1235.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Morén A, Olofsson A, Stenman G, Sahlin P,
Kanzaki T, Claesson-Welsh L, ten Dijke P, Miyazono K and Heldin CH:
Identification and characterization of LTBP-2, a novel latent
transforming growth factor-beta-binding protein. J Biol Chem.
269:32469–32478. 1994.PubMed/NCBI
|
|
13
|
Rifkin DB: Latent transforming growth
factor-beta (TGF-beta) binding proteins: Orchestrators of TGF-beta
availability. J Biol Chem. 280:7409–7412. 2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Liang X, Zhang L, Ji Q, Wang B, Wei D and
Cheng D: miR-421 promotes apoptosis and suppresses metastasis of
osteosarcoma cells via targeting LTBP2. J Cell Biochem: Mar 28,
2019 (Epub ahead of print). doi: 10.1002/jcb.28144.
|
|
15
|
Suri F, Yazdani S and Elahi E: LTBP2
knockdown and oxidative stress affect glaucoma features including
TGFβ pathways, ECM genes expression and apoptosis in trabecular
meshwork cells. Gene. 673:70–81. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ali M, McKibbin M, Booth A, Parry DA, Jain
P, Riazuddin SA, Hejtmancik JF, Khan SN, Firasat S, Shires M, et
al: Null mutations in LTBP2 cause primary congenital glaucoma. Am J
Hum Genet. 84:664–671. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Marin-Garcia J, Goldenthal MJ and Moe GW:
Mitochondrial pathology in cardiac failure. Cardiovasc Res.
49:17–26. 2001.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chen QM and Tu VC: Apoptosis and heart
failure: Mechanisms and therapeutic implications. Am J Cardiovasc
Drugs. 2:43–57. 2002.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Narula J, Pandey P, Arbustini E, Haider N,
Narula N, Kolodgie FD, Dal Bello B, Semigran MJ, Bielsa-Masdeu A,
Dec GW, et al: Apoptosis in heart failure: Release of cytochrome c
from mitochondria and activation of caspase-3 in human
cardiomyopathy. Proc Natl Acad Sci USA. 96:8144–8149.
1999.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Robertson IB, Horiguchi M, Zilberberg L,
Dabovic B, Hadjiolova K and Rifkin DB: Latent TGF-β-binding
proteins. Matrix Biol. 47:44–53. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hyytiäinen M, Taipale J, Heldin CH and
Keski-Oja J: Recombinant latent transforming growth factor
beta-binding protein 2 assembles to fibroblast extracellular matrix
and is susceptible to proteolytic processing and release. J Biol
Chem. 273:20669–20676. 1998.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Vehviläinen P, Hyytiäinen M and Keski-Oja
J: Matrix association of latent TGF-beta binding protein-2 (LTBP-2)
is dependent on fibrillin-1. J Cell Physiol. 221:586–593.
2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Narooie-Nejad M, Paylakhi SH, Shojaee S,
Fazlali Z, Rezaei Kanavi M, Nilforushan N, Yazdani S, Babrzadeh F,
Suri F, Ronaghi M, et al: Loss of function mutations in the gene
encoding latent transforming growth factor beta binding protein 2,
LTBP2, cause primary congenital glaucoma. Hum Mol Genet.
18:3969–3977. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Désir J, Sznajer Y, Depasse F, Roulez F,
Schrooyen M, Meire F and Abramowicz M: LTBP2 null mutations in an
autosomal recessive ocular syndrome with megalocornea,
spherophakia, and secondary glaucoma. Eur J Hum Genet. 18:761–767.
2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
De Sutter J, Pardaens S, Van Hercke D, Van
De Veire N, De Buyzere M, Philippe J, Vanpoucke G and Thomas G:
Latent Transforming growth factor Binding Protein 2 (LTBP2) is
related to phenotypic changes suggestive for HFPEF in stable
outpatients with coronary artery disease and preserved ejection
fraction. Eur Heart J. 34 (Suppl 1)(P5726)2013.
|
|
27
|
Bai Y, Zhang P, Zhang X, Huang J, Hu S and
Wei Y: LTBP-2 acts as a novel marker in human heart failure-a
preliminary study. Biomarkers. 17:407–415. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Jänicke RU, Sprengart ML, Wati MR and
Porter AG: Caspase-3 is required for DNA fragmentation and
morphological changes associated with apoptosis. J Biol Chem.
273:9357–9360. 1998.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yang B, Ye D and Wang Y: Caspase-3 as a
therapeutic target for heart failure. Expert Opin Ther Targets.
17:255–263. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Goumans MJ, van Zonneveld AJ and ten Dijke
P: Transforming growth factor beta-induced
endothelial-to-mesenchymal transition: A switch to cardiac
fibrosis? Trends Cardiovasc Med. 18:293–298. 2008.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wang YJ, Zhou SM, Xu G and Gao YQ:
Interference of phenylethanoid glycosides from cistanche tubulosa
with the MTT Assay. Molecules. 20:8060–8071. 2015.PubMed/NCBI View Article : Google Scholar
|
